CRG Proof of Concept: Commercialization Gap Fund (CGF)
Deadline (Short Submission): 01/09/2016
Please send your application (max. 2 pages) under the following schemes:
- MIDI - Up to 6 months and 35 kEUR
- MAXI - Up to 12 months and 75 kEUR
3rd CRG BioBusiness School (Extended Deadline)
12th-16th September 2016
Based on the great success of the former editions, the 3rd CRG Bio-Business School shall:
- Raise awareness about technology transfer among the participants through lectures and hands-on practical sessions;
- Teach the challenges, opportunities and tools to successfully transfer basic knowledge "from the lab to the marketplace";
- Identify projects with technology transfer/business potential that could otherwise remain undisclosed;
- Match basic science in biomedicine, bioinformatics, etc. with business;
- Have participants function as "signal amplifiers", able to spread the knowledge acquired amongst other colleagues, and apply it to new projects;
- Stimulate a culture of innovation and entrepreneurship.
Registration is free and open online. Click here to register. Deadline (extended) 08 July2016
The TBDO participated in the 2016 BIO International Convention in San Francisco
The BIO International Convention (BIO) attracts over 15,000 biotechnology and pharma leaders who come together for one week of intensive networking and partnering meetings to discover new opportunities and promising partnerships.
Clinical trial opens new avenues for pharmacological therapy in Down's syndrome
CRG and IMIM researchers show in a paper published in The Lancet Neurology that EGCG together with a cognitive stimulation protocol, might improve some cognitive domains in individuals...
A new energy source within the cells
Scientists find evidence of a new energy source within cell nucleus. Their results shed light on how in exceptional situations cells can reprogram gene expression and point at a new player for...
J&J Innovation and Janssen Pharmaceuticals launch the World Without Diseases QuickFire Challenge
Johnson & Johnson Innovation and Janssen Pharmaceuticals, Inc. are bringing together the consumer, medical device and pharmaceutical sectors to award a prize to the person or team who submits the best idea, technology, or solution that will address a critical health need for the world's population, with an emphasis on lung cancer and metabolism.
Projects may be submitted from 1 April to 31 August 2016
Pablo Cironi will moderate the “Open Innovation Models in Drug Discovery” panel at the 9TH Charité Entrepreneurship Summit 2016 in Berlin
The Charité Entrepreneurship Summit attracts annually 400+ international entrepreneurs, scientists, investors, and healthcare industry professionals. This international and cross-disciplinary event offers a unique platform for building new partnerships that will transform the life sciences and the healthcare industry. The 2016 Edition, “Rethink & Transform healthcare”, will feature highly relevant topics, such as the digitalization of health care, the role of open innovation in dramatically improving drug discovery, the prospects of genome editing and healthy aging, the influence of women in changing the healthcare ecosystem, the growing understanding of the impact of gender differences on research and the practice of medicine, and the importance of delivering value-based medicine.
Cell therapy in regenerative medicine from an industrial focus
On initiative of the TBDO, Dr. Miguel Mulet will provide an overview of cell therapy in regenerative medicine from an industrial focus and how this field illustrates particularly well, the challenges and risks of the trip from science to product during PRBB-CRG Session of Friday April 29th 2016 from 12:00-13:00. In this overview, he will touch various aspects:
- Cell therapy as a pharmaceutical product.
- How Mechanism of Action has been a moving target in parallel with product development.
- The intellectual property challenge of protecting inventions involving cells.
- Adapting biologics regulation to cell therapy.
- The long path of clinical development.
- Moving from a laboratory craft to industrial manufacturing.
- Commercialization and Market Access.
Miguel Mulet is Director of Strategy and New Projects in TiGenix, which is a leading European cell therapy company. His primary role at TiGenix is focused on aligning the functions that drive the cell therapy pipeline in Crohn’s Disease and Acute Myocardial Infarct. In addition, and besides business development activities to broaden the current pipeline, he is in charge of advancing the market readiness of the current platforms through implementation of new technologies and process improvement initiatives.
New members and focus on the CRG Business Board
The CRG Business Board, an advisory body whose mission is to provide guidance in business development, investment, entrepreneurial and innovation strategic activities, has been reshuffled.
Rhythm of oscillations in cerebral cortex, key to understanding Down syndrome
Scientists at the CRG and IDIBAPS have made a first-ever identification of the alterations in the neuronal circuit that impact cerebral cortex physiology, and that could be the cause of cognitive...